Altamira Therapeutics
Presencia
Altamira Therapeutics es una empresa que cotiza bajo el símbolo de cotización EARS (CH).
Ejecutivos
Ver el organigrama con sus 7 ejecutivos principales
Biografías más buscadas en Altamira Therapeutics
- Thomas Meyer, Chief Executive Officer and Chairman of the Board
- Margrit Schwarz, Director
- Alain Munoz, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Altamira Therapeutics.
Farmacia
Altamira Therapeutics tiene 1.859 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Altamira Therapeutics
- Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business | Altamira Therapeutics
- Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine | Altamira Therapeutics
- Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis | Altamira Therapeutics
- Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results | Altamira Therapeutics
- Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th | Altamira Therapeutics
- Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 | Altamira Therapeutics
- Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia | Altamira Therapeutics
- Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal | Altamira Therapeutics
- Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering | Altamira Therapeutics
- Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration | Altamira Therapeutics
- View more press releases Close
Redes sociales sobre Altamira Therapeutics
- Altamira Therapeutics en Wikipedia, Google News y Yahoo Finance
- Altamira Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Thomas Meyer 
Llame a Altamira Therapeutics al +41 61...
